Details

Autor(en) / Beteiligte

• Gopinathannair, Rakesh
• Pothineni, Naga Venkata K
• Trivedi, Jaimin R
• Roukoz, Henri
• Cowger, Jennifer
• Ahmed, Mustafa M
• Bhan, Adarsh
• K Ravichandran, Ashwin
• Bhat, Geetha
• Al Ahmad, Amin
• Natale, Andrea
• Di Biase, Luigi
• Slaughter, Mark S
• Lakkireddy, Dhanunjaya

Titel

Amiodarone Use and All-Cause Mortality in Patients With a Continuous-Flow Left Ventricular Assist Device

Ist Teil von

• Journal of the American Heart Association, 2022-06, Vol.11 (11), p.e023762-e023762

Ort / Verlag

England: John Wiley and Sons Inc

Erscheinungsjahr

2022

Quelle

Electronic Journals Library

Beschreibungen/Notizen

• Background Atrial and ventricular arrhythmias are commonly encountered in patients with advanced heart failure, with amiodarone being the most commonly used antiarrhythmic drug in continuous-flow left ventricular assist device (CF-LVAD) recipients. The purpose of this study was to assess the impact of amiodarone use on long-term all-cause mortality in ptients with a CF-LVAD. Methods and Results A retrospective multicenter study of CF-LVAD was conducted at 5 centers including all CF-LVAD implants from 2007 to 2015. Patients were stratified based on pre-CF-LVAD implant amiodarone use. Additional use of amiodarone after CF-LVAD implantation was also evaluated. Primary outcome was all-cause mortality during long-term follow-up. Kaplan-Meier curves were used to assess survival outcomes. Multivariable Cox regression was used to identify predictors of outcomes. Propensity matching was done to address baseline differences. A total of 480 patients with a CF-LVAD (aged 58±13 years, 81% men) were included. Of these, 170 (35.4%) were on chronic amiodarone therapy at the time of CF-LVAD implant, and 310 (64.6%) were not on amiodarone. Rate of all-cause mortality over the follow-up period was 32.9% in the amiodarone group compared with 29.6% in those not on amiodarone ( =0.008). Similar results were noted in the propensity-matched group (log-rank, =0.04). On multivariable Cox regression analysis, amiodarone use at baseline was independently associated with all-cause mortality (hazard ratio, 1.68 [95% CI, 1.1-2.5]; =0.01). Conclusions Amiodarone use was associated with significantly increased rates of all-cause mortality in CF-LVAD recipients. Earlier interventions for arrhythmias to avoid long-term amiodarone exposure may improve long-term outcomes in CF-LVAD recipients and needs further study.